Design
Review
Authors
Loading...
Supports RAS blockade rationale in CV/renal disease; leaves open targeted anti-inflammatory trials.
Key points are not available for this paper at this time.
Ruiz‐Ortega et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: